Insight Brief

The Pivotal Roles Genomics and Flow Cytometry Play in Immuno-oncology Clinical Development

Clinical Trials Laboratories in the Immuno-oncology Setting

Learn how clinical trial laboratories use new innovations in flow cytometry and genomics to advance your immuno-oncology (I-O) studies.

You’ll hear from our Chief Pathologist and Senior Medical Director, Radha Krishnan, M.D., as she also explains: 

  • 3 new challenges contributing to the complexity of I-O therapy development and how new approaches in flow cytometry and genomics are evolving to inform clinical decision making.
  • 6 common I-O assessments, such as gene expression profiling, and their genomic applications.
  • How we used global, harmonized systems and stringent quality control measures to create best practices and help a sponsor move from a Phase I to a Phase III study.

Contact us to learn how we can advance your immuno-oncology drug development program.

Contact Q2 Solutions
Talk To an Expert Contact Our Offices

More Resources

How Immune Repertoire Sequencing Advances Immuno-oncology Biomarker Development Programs
Learn 3 Ways Anatomic Pathology Drives Advancements in Immuno-Oncology
4 Ways Central Laboratories Shape Immuno-oncology Drug Development
View All